Talineuren

DRUG2 trials

Sponsors

InnoMedica Schweiz AG

Conditions

Parkinson Disease

Phase 1

Safety Evaluation of Intravenous Talineuren (TLN) in Parkinson's Disease-affected Patients

TerminatedNCT04976127

InnoMedica Schweiz AGParkinson Disease

Start: 2021-12-11End: 2025-08-06Updated: 2026-04-22

Phase 2

Estimates of the Short-term Efficacy of Talineuren (TLN) and Placebo in Patients With Parkinson Disease

Not yet recruitingNCT06431971

InnoMedica Schweiz AGParkinson Disease

Start: 2024-08-31End: 2025-12-31Target: 40Updated: 2024-05-29

Related Papers

Safety and tolerability of intravenous liposomal GM1 in patients with Parkinson disease: A single-center open-label clinical phase I trial (NEON trial)

PLoS Medicine2025-05-134 citations

Clinical trial protocol.

OPAL (Open@LaTrobe) (La Trobe University)2025-05-13

Laboratory analysis list.

OPAL (Open@LaTrobe) (La Trobe University)2025-05-13

Observed lab values and weekly change.

OPAL (Open@LaTrobe) (La Trobe University)2025-05-13

Clinical assessments data.

OPAL (Open@LaTrobe) (La Trobe University)2025-05-13

PK data of DC cohort.

OPAL (Open@LaTrobe) (La Trobe University)2025-05-13